Topical Application of Trisodium Ascorbyl 6-Palmitate 2-Phosphate Actively Supplies Ascorbate to Skin Cells in an Ascorbate Transporter-Independent Manner

Shuichi Shibuya 1, Ikuyo Sakaguchi 2, Shintaro Ito 2, Eiko Kato 3, Kenji Watanabe 1, Naotaka Izuo 1* and Takahiko Shimizu 1,*

1 Department of Advanced Aging Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba 260-8670, Japan; s-shibuya@chiba-u.jp (S.S.); kng.wtnb@chiba-u.jp (K.W.); ntk.izuo@chiba-u.jp (N.I.)
2 Research & Development Division, Club Cosmetics Co., Ltd., Ikoma, Nara 630-0222, Japan; ikuyos@clubcosmetics.co.jp (I.S.); sito@clubcosmetics.co.jp (S.I.)
3 Functional Chemicals Division, Showa Denko K.K. Minato-ku, Tokyo 105-8518, Japan; kato.eiko.xhzqn@showadenko.com

* Correspondence: shimizu@chiba-u.jp; Tel.: +81-43-222-7171; Fax: +81-43-226-2095

Received: 2 May 2017; Accepted: 19 June 2017; Published: 22 June 2017

Abstract: Ascorbic acid (AA) possesses multiple beneficial functions, such as regulating collagen biosynthesis and redox balance in the skin. AA derivatives have been developed to overcome this compound’s high fragility and to assist with AA supplementation to the skin. However, how AA derivatives are transferred into cells and converted to AA in the skin remains unclear. In the present study, we showed that AA treatment failed to increase the cellular AA level in the presence of AA transporter inhibitors, indicating an AA transporter-dependent action. In contrast, trisodium ascorbyl 6-palmitate 2-phosphate (APPS) treatment significantly enhanced the cellular AA level in skin cells despite the presence of inhibitors. In ex vivo experiments, APPS treatment also increased the AA content in a human epidermis model. Interestingly, APPS was readily metabolized and converted to AA in keratinocyte lysates via an intrinsic mechanism. Furthermore, APPS markedly repressed the intracellular superoxide generation and promoted viability associated with an enhanced AA level in Sod1-deficient skin cells. These findings indicate that APPS effectively restores the AA level and normalizes the redox balance in skin cells in an AA transporter-independent manner. Topical treatment of APPS is a beneficial strategy for supplying AA and improving the physiology of damaged skin.

Keywords: ascorbic acid; ascorbic acid transporter; ascorbic acid derivative; skin

1. Introduction

Ascorbic acid (AA) is a major soluble vitamin distributed in the tissues of all organisms, including animals and plants. In humans, organs such as the skin contain millimolar-order levels of AA, while plasma contains relatively low levels of AA (40–60 µM) [1,2]. Environmental factors such as lifestyle and nutrients consumed in the diet regulate the physiological kinetics of AA for maintaining organ homeostasis in the body. For example, smoking and an insufficient intake of vegetables and fruits adversely affect the AA status in the human body [3].

Accumulating evidence has shown that the chemical characteristics of AA as an electron donor play an important role in redox regulation in the human body [2,4–6]. AA also regulates many oxidase and hydroxylase activities as a cofactor to maintain cellular metabolism [4,7]. In particular, AA is an essential cofactor for post-translational modifications by lysyl oxidase and prolyl hydroxylase in
collagen formation and further enhances the transcript levels of type I and III collagen genes [5,8].
AA also interferes with pigment production by interacting with copper ions at the tyrosinase activity site and reducing dopaquinone [9]. In this context, AA supplementation has been largely used to maintain the skin function and prevent skin aging in cosmetic and supplement fields worldwide.

As AA is highly fragile and not very liposoluble, allowing it to penetrate the skin and sustain its physiological function over a long period of time is difficult. To increase the stability and liposolubility of AA, various AA derivatives have been developed for dermatological application [10,11]. A phosphate group- and long hydrophobic chain-conjugated derivative, torisodium ascorbyl 6-palmitate 2-phosphate (APPS), was also developed to increase liposolubility [12]. In clinical applications, Inui and Itami have reported that topical treatment with APPS lotion for four weeks attenuated perifollicular pigmentation in female subjects [13].

AA is incorporated into cells through two types of transporters: sodium-dependent vitamin C transporters (SVCT1 and SVCT2) and hexose transporters (GLUT1, GULT3, and GLUT4) [14]. AA and oxidized AA, known as dehydroascorbic acid (DHAA), are separately transported into the cytoplasm by SVCTs and GULTs, respectively. However, precisely how the AA derivative is transported to skin cells and converted to AA remains unclear.

In the present study, we measured the cellular intake and transporter utilization of AA or APPS to estimate the intake efficiency of AA in skin cells. We also investigated the conversion mechanism of APPS to AA in cells. Furthermore, we investigated the redox regulation by APPS treatment in skin cells associated with oxidative damage. We then discussed the potential utility of APPS in AA supplementation and proposed an ideal protocol for applying AA derivatives to skin.

2. Materials and Methods

2.1. Materials

APPS (Figure 1) was provided by Showa Denko K.K. (Tokyo, Japan).

![Figure 1. The structures of ascorbic acid (AA), A6Pal, APS, and APPS. L-ascorbyl 6-palmitate (A6Pal) is additionally conjugated with a long hydrophobic chain. Sodium ascorbyl 2-phosphate (APS) is additionally conjugated with a phosphate group. Torisodium ascorbyl 6-palmitate 2-phosphate (APPS) is additionally conjugated with a phosphate group and a long hydrophobic chain.](image-url)

2.2. Measurement of AA Content in Skin Cells

Human fibroblasts (TIG118) were purchased from Health Science Research Resources Bank (Tokyo, Japan). TIG118 cells were maintained in DMEM (Nacalai Tesque, Kyoto, Japan) supplemented
with 10% FBS (Life Technologies Corporation, Carlsbad, CA, USA), 100 units/mL of penicillin (Sigma-Aldrich, St. Louis, MO, USA), and 0.1 mg/mL of streptomycin (Sigma-Aldrich) at 37 °C in a humidified incubator with 5% CO2. Cells were pre-incubated with or without phorbol 12-myristate 13-acetate (PMA) and glucose for 1 h to inhibit ascorbate transporters [15,16]. After pre-incubation, cells were washed three times with PBS and cultured for 1 h in culture medium with or without 10 µM AA and 10 µM APPS. Isolated cells were sonicated with 5.4% metaphosphoric acid (Wako, Osaka, Japan) to suppress oxidation. The homogenate was centrifuged at 10,000×g for 15 min at 4 °C, and the supernatant was then used for the assay. The AA level was measured using the Vitamin C quantitative determination Kit (SHIMA Laboratories, Tokyo, Japan) in accordance with the manufacturer’s instructions (Figure 2).

2.3. A Kinetic Analysis of APPS Metabolism in Vitro

Human keratinocytes (NHEKs) were purchased from KURABO Industries (Osaka, Japan). NHEKs were cultured in HuMedia KG-2 (KURABO Industries) in accordance with the manufacturer’s instructions. Cultured keratinocytes were collected and homogenized with HEPES buffer (1 × 10⁶ cells/mL). To the homogenate was added 300 µM APPS (final concentration), and the solution was incubated at 37 °C. At each sampling point, the homogenate was centrifuged at 10,000×g for 15 min at 4 °C, and the supernatant was collected. Samples were filtered through a 0.22-µm membrane and measured for APPS and its metabolites (Figure 1) by high-performance liquid chromatography (HPLC) using a Shimadzu Prominence 20A system (Shimadzu Corporation, Kyoto, Japan). The separation conditions of AA, APS, A6Pal, and APPS were as follows, respectively: (1) for AA, Shodex Asahipak NH2P-50 4E column (Showa Denko K.K., Tokyo, Japan); detection wavelength, 254 nm; mobile phase, 60 mM H₃PO₄/acetonitrile (20/80); flow rate, 0.8 mL/min; (2) for APS, Shodex Asahipak NH2P-50 4E column; detection wavelength, 245 nm; mobile phase, 45 mM Na₂SO₄, 50 mM H₃PO₄/acetonitrile (80/20); flow rate, 1 mL/min; (3) for A6Pal and APPS, Shodex Silica C18P 4E column (Showa Denko K.K., Tokyo, Japan); detection wavelength, 265 nm; mobile phase, 30 mM K₂HPO₄ (pH 7.0)/tetrahydrofuran (35/65); flow rate, 0.7 mL/min. The levels of APPS and its metabolites were determined on the basis of the peak area of the standard AA curve (Figure 3A).

![Figure 2](image-url)

**Figure 2.** APPS upregulates the cellular AA level in an AA transporter-independent manner. (A) Intracellular ascorbic acid (AA) contents in human cells treated with 10 µM AA or 10 µM APPS for 1 h. These data represent the mean ± SE; * p < 0.05; (B) Intracellular AA contents in human cells. Human cells were pre-incubated with or without 10 µM PMA and 10 µM glucose for 1 h. After pre-incubation, cells were washed and cultured for 1 h in culture medium with or without 10 µM AA and 10 µM APPS. These data represent the mean ± SEM; * p < 0.05 vs. no treatment control, ** p < 0.01 vs. no treatment control.
Figure 3. APPS is converted to AA by endogenous convertases. (A) A kinetics analysis of APPS metabolites including AA, A6Pal, and APS in keratinocyte lysates; (B) A human epidermal skin model (LabCyte EPI-MODEL) was used in ex vivo experiments; (C) AA contents in epidermis and conditioned medium in an ex vivo human epidermal skin model treated with APPS at various doses. These data represent the mean ± SEM; * p < 0.05 vs. no AA treatment, ** p < 0.01 vs. no AA treatment.

2.4. Treatment with APPS in a Human Epidermal Skin Model

A human epidermal skin model (LabCyte EPI-MODEL; J-TEC, Aichi, Japan) was cultured in accordance with the manufacturer’s instructions (Figure 3B). The skin model was treated with APPS solution and cultured at 37 °C for 24 h. After incubation, skin tissues and conditioned medium were collected. Skin tissues (10 mm diameter) were homogenized with 50% ethanol (three tissues/1.5 mL) using a Biomasher (Nippi, Ibaraki, Japan). The skin homogenate was centrifuged at 15,000×g for 30 s at 4 °C. To the supernatant and conditioned medium was added 66% metaphosphoric acid (10 µL/200 µL supernatant), and this solution was then incubated first at 4 °C for 30 min and then with 22 mg/mL dithioerythritol (10 µL/200 µL supernatant; MP Biomedicals, LLC, Illkirch, France) at 4 °C for 30 min. The supernatant was centrifuged and filtered for a later analysis. The levels of APPS and its metabolites were measured with HPLC equipped with a Shodex Asahipak NH2P-50 4E column. The separation conditions were as follows: detection wavelength, 245 nm; mobile phase, 60 mM H₃PO₄/acetonitrile (20/80) (Figure 3C).

2.5. Measurement of AA Content in Sod1-deficient Cells

Sod1+/+ and Sod1−/− dermal fibroblasts were cultured in accordance with a previous description [17]. Cells were cultured for 6 h in culture medium with or without 10 µM AA and 10 µM APPS. The AA level was measured using the Vitamin C quantitative determination Kit (SHIMA Laboratories, Tokyo, Japan) as described above (Figure 4A).
2.6. Intracellular Reactive Oxygen Species

*Sod1*+/+ and *Sod1*−/− dermal fibroblasts were cultured with 10 µM AA or 10 µM APPS for 24 h in 1% O₂, followed by incubation under 20% O₂ condition for 16 h to induce oxidative stress. After treatment, the fibroblasts were stained with 10 µM dihydroethidium (DHE) fluorescent probe (Life Technologies Corporation, Carlsbad, CA, USA) and 10 µM Hoechst 33342 (Merck Millipore, Darmstadt, Germany) for 20 min under 20% O₂. The intracellular superoxide (O₂−) generation was calculated as the DHE-positive area per nuclei number using fluorescent microscopy with the Leica Qwin V3 image software program (Leica Microsystems, Buffalo Grove, IL, USA).

2.7. Cell Viability and Proliferation Assay

*Sod1*+/+ and *Sod1*−/− skin cells were cultured, and the number of cells was directly counted as described previously [17]. The collected medium was centrifuged at 400× g for 5 min at 4°C, and the supernatant was used for the subsequent assays. The lactate dehydrogenase (LDH) level was measured using the LDH cytotoxicity assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) in accordance with the manufacturer’s instructions.

2.8. Statistical Analyses

The statistical analyses were performed using Student’s *t*-test for comparisons between two groups and Tukey’s test for comparisons among three groups. Differences between the data were considered significant when the *p* values were less than 0.05. All data are expressed as the mean ± standard error of the mean (SEM).

3. Results

3.1. APPS Positively Increases the Intracellular AA Contents in an AA Transporter-Independent Manner

AA has been largely used in cosmetics to maintain the skin function because of its beneficial effects, such as antioxidation and regulation of collagen biosynthesis. However, its high fragility as well as low liposolubility limit its penetration into the skin and physiological action. A number of AA derivatives have been developed to overcome these disadvantages [10,11]. One such derivative, APPS, was generated through the conjugation of a phosphate group and a long hydrophobic chain (Figure 1).

In order to evaluate the permeability of AA, we treated human skin cells with AA or APPS and biochemically measured the cellular AA contents (Figure 2A). APPS treatment for 1 h significantly increased the cellular AA levels by 4.1-fold compared to the control skin, whereas AA treatment increased them only by 2.3-fold (Figure 2A). AA is usually transported into cells through AA transporters, such as SVCTs and GLUTs [18,19]. To investigate the transporter utilization of APPS and AA, we pre-treated human skin cells with PMA and glucose as AA transport inhibitors. As shown in Figure 2B, PMA and glucose markedly inhibited the uptake of AA with only AA addition alone. In contrast, APPS treatment sustained high levels of cellular AA in fibroblasts in the presence of both PMA and glucose (Figure 2B). These results demonstrated that APPS supplementation effectively and stably enhanced the intracellular AA contents in an AA transporter-independent manner.

3.2. Topical APPS is Effectively Converted to AA in Skin Cells

Next, to investigate the conversion mechanism of APPS to AA in skin cells, we incubated APPS in homogenates of human keratinocytes and monitored the dynamics of APPS and other metabolites, including AA, L-ascorbyl 6-palmitate (A6Pal), and sodium ascorbyl 2-phosphate (APS) (Figure 1). As expected, the APPS contents were rapidly reduced at 2 h after incubation (Figure 3A). In contrast, the contents of A6Pal, a metabolite with phosphate group cleavage, were increased at 2 h after incubation and gradually decreased until 8 h (Figure 3A). Concomitantly, the AA contents were gradually increased in a time-dependent manner (Figure 3A). Interestingly, the APS contents were not altered in the
homogenates (Figure 3A). Indeed, potent phosphatase and esterase activities have been detected in human as well as rodent skin tissue [20–23]. Taken together, these present and previous findings suggest that endogenous phosphatases first cleave the phosphate group of APPS followed by intrinsic esterases to release the palmitate group of A6Pal, resulting in the production of AA in the conversion process.

To estimate the permeability of APPS, we applied APPS to our human epidermis models, which consist of a stratum corneum layer on keratinocyte culture (Figure 3B). Skin tissues without APPS treatment possessed AA contents below detection limit. When we treated the model with APPS for 24 h, the AA contents in the tissue was significantly increased in a dose-dependent manner (Figure 3C), suggesting that APPS was converted to AA in the tissue. Furthermore, the AA contents in the conditioned medium at the bottom of the dish were also significantly increased in cases of high-dose treatment (Figure 3C). These results indicated that APPS is effectively converted to AA and transferred into skin cells.

3.3. APPS Attenuates Cellular Oxidative Damage in Skin

SOD1, a major antioxidant enzyme in cytoplasm, plays an important role in maintaining the cellular redox balance. SOD1 loss significantly exhibited low viability associated with enhanced intracellular reactive oxygen species and cellular damage [24–32]. Interestingly, we failed to detect trace levels of cellular AA in Sod1+/− cells, indicating impairment of the AA-glutathione cycle and redox balance (Figure 4A). APPS and AA treatment enhanced the cellular AA level in both Sod1+/− and Sod1+/+ skin cells (Figure 4A). Pre-treatment with APPS and AA completely suppressed the O$_2^-$ generation in Sod1+/− cells, resulting in production at the same level as in the Sod1+/+ cells (Figure 4B). APPS treatment also improved the viability and promoted proliferation associated with the suppression of cellular damage (Figure 4C). These findings showed that APPS ameliorates cellular damage by increasing the cellular AA level in damaged skin cells.

Figure 4. APPS elevates the cellular AA levels and attenuates cellular damage in skin cells. (A) Intracellular AA contents in Sod1+/+ and Sod1−/− cells treated with 10 µM AA or 10 µM APPS for 6 h; (B) For the measurement of intracellular reactive oxygen species, cultured Sod1+/+ and Sod1−/− cells treated with 10 µM AA or 10 µM APPS for 24 h were stained with dihydroethidium. The scale bar represents 100 µm; (C) The viability and proliferation of Sod1+/+ and Sod1−/− cells with or without 10 µM APPS treatment for 96 h were analyzed. The lactate dehydrogenase activity in the conditioned medium used to culture the Sod1+/+ and Sod1−/− skin cells for 96 h was measured. These data represent the mean ± SEM; * p < 0.05, ** p < 0.01.
4. Discussion

4.1. APPS is Effectively Converted to AA by Cellular Convertases, Resulting in AA Transport into the Cytoplasm of Skin Cells in an AA Transporter-Independent Manner

Since skin innately includes relatively high levels of AA (approximately 50-fold that of plasma) [1,2], the skin AA level generally depends on and is maintained by AA transport activity rather than concentration-directed diffusion. In the present study, we showed that APPS treatment effectively supplied AA to the cytoplasm in skin cells compared to AA treatment in vitro (Figure 2A). APPS, but not AA, significantly increased the intracellular AA level even though both SVCTs and GLUTs were inhibited (Figure 2B). This preferential capacity of APPS is due to an AA transporter-independent action. As shown in Figure 3A, the addition of APPS to cell lysate rapidly increased the content of A6Pal, but not APS, and then gradually increased the AA content. We also found that APPS efficiently penetrated and converted AA in epidermal cells, leading to passed through AA in the conditioned medium in a three-dimensional epidermis model (Figure 3C). Since skin cells possess high phosphatase and esterase activity [20–23], endogenous cellular convertases can cleave the phosphate and palmitate groups of APPS.

Glatz et al. reported that fatty acids, including palmitate, can directly traverse the plasma membrane and that albumin proteins located at the outer cell surface may play an additional role in the delivery of fatty acids into the cytoplasm in cells [33,34]. These multiple transport mechanisms of fatty acid may help facilitate the permeability of skin cells to APPS, leading to its conversion to AA by endogenous cellular enzymes, such as phosphatases and esterases.

4.2. APPS Improves the AA Level and Skin Function by Regulating Redox Balance

In the present study, in vitro experiments showed that the supply of AA by APPS treatment effectively increased the cellular AA level and suppressed the O$_2^-$ generation associated with improved viability in Sod1$^{-/-}$ cells, resulting in physiological redox level (Figure 4A,B). We also showed that treatment with APPS significantly promoted the proliferation and migration of Sod1$^{-/-}$ skin cells associated with the suppression of LDH activity (Figure 4C). Du et al. reported that APPS treatment improved viability of PC12 cells treated with hydrogen peroxide [12], suggesting that APPS treatment protect cells from various types of oxidative damage. AA highly reacts with oxygen and O$_2^-$, resulting in oxidized AA forms such as mono-DHAA and DHAA [35,36]. Mono-DHAA and DHAA serve as AA radicals to capture electrons and can also be recycled back into AA by direct reduction in the AA-glutathione cycle [37]. Under highly oxidative conditions, mono-DHAA and DHAA are further degraded via hydrolysis or oxidation to 2,3-diketogulonic acid with no AA potency [38]. These results suggest that AA supplementation by APPS may increase AA recycling via these systems, resulting in improvement in the redox balance in damaged skin, such as under conditions of Sod1 deficiency.

Long chain fatty acids, including palmitate, are required for the lipid synthesis in skin to maintain tissue homeostasis [39]. Kim et al. reported that ultraviolet (UV) irradiation and aging stress caused a reduction in the contents of palmitate, eicosatrienoic acid, and other fatty acid in skin [40]. Treatment with eicosatrienoic acid downregulated the expression of MMP1 in human keratinocytes irradiated by UV [40]. Palmitoleic acid, metabolites from palmitate, also inhibited the gene expression of Mmp9 and RANKL-induced NF-$\kappa$B activation in murine macrophages [41]. These results suggest that fatty acid supplementation to the skin may act as a regulator of skin homeostasis. In this context, palmitate cleaved from APPS in the skin might also protect skin cells from exogenous insults, such as pro-oxidants and UV.

4.3. Topical Application of APPS for Damaged Skin

The SVCT function is obligatorily dependent on a favorable inward gradient for Na$^+$, which in turn is sustained by the continuous extrusion of Na$^+$ by ATP-dependent Na$^+/K^+$-ATPase [42,43]. Indeed, the replacement of Na$^+$ with K$^+$, Li$^+$, or choline almost completely abolishes the AA uptake [42,44].
Furthermore, SVCT2 is modulated by Ca\(^{2+}\) and Mg\(^{2+}\) ions, which switch the transporter from an inactive to an active form [45]. We previously reported that Sod1 deficiency induced age-related skin atrophy and a reduction in the AA contents in skin [25]. We also provided evidence that Sod1\(^{-/-}\) skin cells showed aberrantly increased intracellular Ca\(^{2+}\) levels (data not shown) and loss of mitochondrial membrane potential associated with ATP depletion [46], indicating alteration of intracellular Ca\(^{2+}\) and ATP utilization in skin. We previously demonstrated that the topical treatment of APPS completely cured atrophy and oxidative damage in Sod1\(^{-/-}\) skins [17,27]. Taken together, these findings also implied that APPS thus appears to be useful for the supply of AA to the skin and also for the mitigation of oxidative damage via penetration mechanisms independent from AA transporters. Topical treatment of APPS is a beneficial strategy for supplying AA and improving the physiology of damaged skin.

Acknowledgments: We thank Yusuke Ozawa, Toshihiko Toda, and Kinue Iizuka (Chiba University) for their valuable technical assistance.

Author Contributions: S.S. and T.S. designed the study. S.S. and T.S. wrote the manuscript. S.S., I.S., S.I. and E.K. performed the study. S.S., I.S., S.I. and E.K. analyzed the data. K.W. and N.I. edited the article. T.S. coordinated and directed the project.

Conflicts of Interest: This research was supported by funds from Club Cosmetics Company (Nara, Japan) and Showa Denko Company (Tokyo, Japan). The APPS was provided by Showa Denko (Tokyo, Japan). This does not alter the authors’ adherence to all Nutrients policies on sharing data and materials.

References

1. Levine, M.; Wang, Y.; Padayatty, S.J.; Morrow, J. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. USA 2001, 98, 9842–9846. [CrossRef] [PubMed]
2. Harrison, F.E.; May, J.M. Vitamin C function in the brain: Vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med. 2009, 46, 719–730. [CrossRef] [PubMed]
3. Loria, C.M.; Klag, M.J.; Caulfield, L.E.; Whelton, P.K. Vitamin C status and mortality in US adults. Am. J. Clin. Nutr. 2000, 72, 139–145. [PubMed]
4. Padayatty, S.J.; Katz, A.; Wang, Y.; Eck, P.; Kwon, O.; Lee, J.H.; Chen, S.; Corpe, C.; Dutta, A.; Dutta, S.K.; et al. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J. Am. Coll. Nutr. 2003, 22, 18–35. [CrossRef] [PubMed]
5. Du, J.; Cullen, J.J.; Buettner, G.R. Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta 2012, 1826, 443–457. [CrossRef] [PubMed]
6. Petruk, G.; Raiola, A.; Del Giudice, R.; Barone, A.; Frusciante, L.; Rigano, M.M.; Monti, D.M. An ascorbic acid-enriched tomato genotype to fight UVA-induced oxidative stress in normal human keratinocytes. J. Photochem. Photobiol. 2016, 163, 284–289. [CrossRef] [PubMed]
7. Saito, K.; Hosoi, E.; Ishigami, A.; Yokoyama, T. Vitamin C and physical performance in the elderly. In Oxidative Stress and Dietary Antioxidants; Preedy, V.R., Ed.; Academic Press: New York, NY, USA, 2014; pp. 119–128.
8. Duarte, T.L.; Almeida, I.F. Vitamin C, gene expression and skin health. In Handbook of Diet, Nutrition and the Skin; Preedy, V.R., Ed.; Wageningen Academic Publishers: Wageningen, The Netherlands, 2012; pp. 115–128.
9. Rendon, M.I.; Gaviria, J.I. Review of skin-lightening agents. Dermatol. Surg. 2005, 31, 886–889. [CrossRef] [PubMed]
10. Lupo, M.P. Antioxidants and vitamins in cosmetics. Clin. Dermatol. 2001, 19, 467–473. [CrossRef]
11. Palma, S.; Manzo, R.; Lo Nostrò, P.; Allemandi, D. Nanostructures from alkyl vitamin C derivatives (ASCn): Properties and potential platform for drug delivery. Int. J. Pharm. 2007, 345, 26–34. [CrossRef] [PubMed]
12. Du, C.B.; Liu, J.W.; Su, W.; Ren, Y.H.; Wei, D.Z. The protective effect of ascorbic acid derivative on PC12 cells: Involvement of its ROS scavenging ability. Life Sci. 2003, 74, 771–780. [CrossRef] [PubMed]
13. Inui, S.; Itami, S. Perifollicular pigmentation is the first target for topical vitamin C derivative ascorbyl 2-phosphate 6-palmitate (APPS): Randomized, single-blinded, placebo-controlled study. J. Dermatol. 2007, 34, 221–223. [CrossRef] [PubMed]
14. Tian, W.; Wang, Y.; Xu, Y.; Guo, X.; Wang, B.; Sun, L.; Liu, L.; Cui, F.; Zhuang, Q.; Bao, X.; et al. The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity. *J. Biol. Chem.* 2014, 289, 3339–3351. [CrossRef] [PubMed]

15. Liang, W.J.; Johnson, D.; Ma, L.S.; Jarvis, S.M.; Wei-Jun, L. Regulation of the human vitamin C transporters expressed in COS-1 cells by protein kinase C. *Am. J. Physiol. Cell Physiol.* 2002, 283, C1696–C1704. [CrossRef] [PubMed]

16. McNulty, A.L.; Stabler, T.V.; Vail, T.P.; McDaniel, G.E.; Kraus, V.B. Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbic acid in the joint. *Arthritis Rheum.* 2005, 52, 2676–2685. [CrossRef] [PubMed]

17. Shibuya, S.; Ozawa, Y.; Toda, T.; Watanabe, K.; Tometsuka, C.; Ogura, T.; Koyama, Y.; Shimizu, T. Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. *Biosci. Biotechnol. Biochem.* 2014, 78, 1212–1220. [CrossRef] [PubMed]

18. Tsukaguchi, H.; Tokui, T.; Mackenzie, B.; Berger, U.V.; Chen, X.Z.; Wang, Y.; Brubaker, R.F.; Hediger, M.A. A family of mammalian Na+–dependent L-ascorbic acid transporters. *Nature* 1999, 399, 70–75. [PubMed]

19. Rumsey, S.C.; Kwon, O.; Xu, G.W.; Burant, C.F.; Simpson, I.; Levine, M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. *J. Biol. Chem.* 1997, 272, 18982–18989. [CrossRef] [PubMed]

20. Partanen, S. Histochromically demonstrable acid phosphotyrosine phosphatase activity in human tissues. *Eur. J. Histochem.* 1998, 42, 171–181. [PubMed]

21. Jewell, C.; Ackermann, C.; Payne, N.A.; Fate, G.; Voorman, R.; Williams, F.M. Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver. *Drug Metab. Dispos.* 2007, 35, 2015–2022. [CrossRef] [PubMed]

22. Jewell, C.; Prusakiewicz, J.J.; Ackermann, C.; Payne, N.A.; Fate, G.; Williams, F.M. The distribution of esterases in the skin of the minipig. *Toxicol. Lett.* 2007, 173, 118–123. [CrossRef] [PubMed]

23. Prusakiewicz, J.J.; Ackermann, C.; Voorman, R. Comparison of skin esterase activities from different species. *Pharm. Res.* 2006, 23, 1517–1524. [CrossRef] [PubMed]

24. Shibuya, S.; Ozawa, Y.; Inagaki, J.; Irie, K.; et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. *J. Biol. Chem.* 2011, 286, 44557–44568. [CrossRef] [PubMed]

25. Murakami, K.; Inagaki, J.; Saito, M.; Ikeda, Y.; Tsuda, C.; Noda, Y.; Kawakami, S.; Shirasawa, T.; Shimizu, T. Skin atrophy in cytoplasmic SOD-deficient mice. *Biosci. Biotechnol. Biochem.* 2009, 73, 2017–2024. [CrossRef] [PubMed]

26. Watanabe, K.; Shibuya, S.; Ozawa, Y.; Irie, K.; et al. Superoxide dismutase 1 loss disturbs intracellular redox signaling, resulting in global age-related pathological changes. *BioMed Res. Int.* 2014, 2014, 140165. [CrossRef] [PubMed]

27. Murakami, K.; Murata, N.; Noda, Y.; Kohara, K.; et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. *Biochem. Biophys. Res. Commun.* 2009, 382, 457–461. [CrossRef] [PubMed]

28. Murakami, K.; Murata, N.; Noda, Y.; Tahara, S.; Kaneko, T.; Kinoshita, N.; Hatsuta, H.; Murayama, S.; Barnham, K.J.; Irie, K.; et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. *J. Biol. Chem.* 2011, 286, 44557–44568. [CrossRef] [PubMed]

29. Murakami, K.; Murata, N.; Ozawa, Y.; Kinoshita, N.; Irie, K.; Shirasawa, T.; Shimizu, T. Vitamin C restores behavioral deficits and amyloid-beta oligomerization without affecting plaque formation in a mouse model of Alzheimer’s disease. *J. Alzheimer’s Dis.* 2011, 26, 7–18.

30. Nojiri, H.; Saita, Y.; Morikawa, D.; Kobayashi, K.; Tsuda, C.; Miyazaki, T.; Saito, M.; Marumo, K.; Yonezawa, I.; Kaneko, K.; et al. Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking. *J. Bone Miner. Res.* 2011, 26, 2682–2694. [CrossRef] [PubMed]

31. Morikawa, D.; Nojiri, H.; Saita, Y.; Kobayashi, K.; Watanabe, K.; Ozawa, Y.; Koike, M.; Asou, Y.; Takaku, T.; Kaneko, K.; et al. Cytoplasmic reactive oxygen species and SOD1 regulate bone mass during mechanical unloading. *J. Bone Miner. Res.* 2013, 28, 2368–2380. [CrossRef] [PubMed]

32. Morikawa, D.; Itoigawa, Y.; Nojiri, H.; Sano, H.; Itoi, E.; Saito, Y.; Kaneko, K.; Shimizu, T. Contribution of oxidative stress to the degeneration of rotator cuff entheses. *J. Shoulder Elb. Surg.* 2014, 23, 628–635. [CrossRef] [PubMed]
33. Glatz, J.F.; Luiken, J.J.; van Nieuwenhoven, F.A.; Van der Vusse, G.J. Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 1997, 57, 3–9. [CrossRef]
34. Glatz, J.F. Lipids and lipid binding proteins: A perfect match. Prostaglandins Leukot. Essent. Fatty Acids 2015, 93, 45–49. [CrossRef] [PubMed]
35. Nishikimi, M. Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem. Biophys. Res. Commun. 1975, 63, 463–468. [CrossRef]
36. Bielski, B.H.; Richter, H.W.; Chan, P.C. Some properties of the ascorbate free radical. Ann. N. Y. Acad. Sci. 1975, 258, 231–237. [CrossRef] [PubMed]
37. Wells, W.W.; Xu, D.P. Dehydroascorbate reduction. J. Bioenerg. Biomembr. 1994, 26, 369–377. [CrossRef] [PubMed]
38. Gibbons, E.; Allwood, M.C.; Neal, T.; Hardy, G. Degradation of dehydroascorbic acid in parenteral nutrition mixtures. J. Pharm. Biomed. Anal. 2001, 25, 605–611. [CrossRef]
39. Nakamura, M.T.; Yudell, B.E.; Loor, J.J. Regulation of energy metabolism by long-chain fatty acids. Prog. Lipid. Res. 2014, 53, 124–144. [CrossRef] [PubMed]
40. Kim, E.J.; Kim, M.K.; Jin, X.J.; Oh, J.H.; Kim, J.E.; Chung, J.H. Skin aging and photoaging alter fatty acids composition, including 11,14,17-eicosatrienoic acid, in the epidermis of human skin. J. Korean Med. Sci. 2010, 25, 980–983. [CrossRef] [PubMed]
41. Van Heerden, B.; Kasonga, A.; Kruger, M.C.; Coetsee, M. Palmitoleic acid inhibits RANKL-induced osteoclastogenesis and bone resorption by suppressing NF-κB and MAPK signalling pathways. Nutrients 2017, 9, 441. [CrossRef] [PubMed]
42. Castro, M.; Caprile, T.; Astuya, A.; Millan, C.; Reinicke, K.; Vera, J.C.; Vasquez, O.; Aguayo, L.G.; Nualart, F. High-affinity sodium-vitamin C co-transporters (SVCT) expression in embryonic mouse neurons. J. Neurochem. 2001, 78, 815–823. [CrossRef] [PubMed]
43. Garcia, M.D.L.; Salazar, K.; Millan, C.; Rodriguez, F.; Montecinos, H.; Caprile, T.; Silva, C.; Cortes, C.; Reinicke, K.; Vera, J.C.; et al. Sodium vitamin C cotransporter SVCT2 is expressed in hypothalamic glial cells. Glia 2005, 50, 32–47. [CrossRef] [PubMed]
44. Rajan, D.P.; Huang, W.; Dutta, B.; Devoie, L.D.; Leibach, F.H.; Ganapathy, V.; Prasad, P.D. Human placental sodium-dependent vitamin C transporter (SVCT2): Molecular cloning and transport function. Biochem. Biophys. Res. Commun. 1999, 262, 762–768. [CrossRef] [PubMed]
45. Godoy, A.; Ormazabal, V.; Moraga-Cid, G.; Zuniga, F.A.; Sotomayor, P.; Barra, V.; Vasquez, O.; Montecinos, V.; Mardones, L.; Guzman, C.; et al. Mechanistic insights and functional determinants of the transport cycle of the ascorbic acid transporter SVCT2. Activation by sodium and absolute dependence on bivalent cations. J. Biol. Chem. 2007, 282, 615–624. [CrossRef] [PubMed]
46. Watanabe, K.; Shibuya, S.; Koyama, H.; Ozawa, Y.; Toda, T.; Yokote, K.; Shimizu, T. Sod1 loss induces intrinsic superoxide accumulation leading to p53-mediated growth arrest and apoptosis. Int. J. Mol. Sci. 2013, 14, 10998–11010. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).